ENTYCE® (capromorelin oral solution)

Turn on appetite

Finally, appetite stimulation is in your control.

Until now, there have been limited therapeutic options to restore appetite. That’s why we created ENTYCE, the only FDA-approved therapeutic designed to safely and effectively stimulate appetite in dogs. ENTYCE works by mimicking ghrelin, the “hunger hormone,” and is appropriate to treat inappetence caused by chronic and acute conditions.

 

If the manufacturing transfer is approved by the FDA, Aratana believes it would be able to make ENTYCE commercially available by the fall of 2017.

Turn on appetite

Finally, appetite stimulation is in your control.

Until now, there have been limited therapeutic options to restore appetite. That’s why we created ENTYCE, the only FDA-approved therapeutic designed to safely and effectively stimulate appetite in dogs. ENTYCE works by mimicking ghrelin, the “hunger hormone,” and is appropriate to treat inappetence caused by chronic and acute conditions.

 

Aratana intends to commercially launch ENTYCE by the fall of 2017.

More than 10 million dogs in the United States present annually to their veterinarian with the symptom of inappetence.

Almost any disease can manifest or develop decreased appetite (hyporexia), complete lack of appetite (anorexia) or changes in appetite (dysrexia). Inappetence can be the first sign, and may be the only sign a dog is sick or has an underlying health condition. Prolonged inappetence, if left untreated, can become even more detrimental to the patient than the underlying primary disease. In addition, inappetence can cause a negative perception of the dog’s quality of life to the caregiver, which may be especially distressful and is often perceived as evidence of suffering.

Historically, with no FDA-approved drugs to stimulate appetite, veterinarians have had limited therapeutic options. Now, veterinarians have an FDA-approved appetite stimulant in dogs, ENTYCE (capromorelin oral solution).

The regulation of appetite involves the coordination of many signals from the brain (mainly the hypothalamus), peripheral tissues (such as adipose tissue) and endocrine system (such as ghrelin, leptin and insulin).

ENTYCE is a ghrelin receptor agonist that mimics the effect of ghrelin (the “hunger hormone”). Like naturally occurring ghrelin, ENTYCE binds to specific cell receptors and affects signaling in the hypothalamus to cause the feeling of hunger, which in turn, leads to food intake. Ghrelin also impacts energy homeostasis and metabolism, and is essential for survival.

ENTYCE is supplied in a 30 mg/mL flavored once-daily oral solution for the treatment of inappetence in dogs.

ENTYCE is the ONLY FDA-approved veterinary therapeutic labeled for stimulation of appetite in dogs and could serve as an important tool in the medical management of conditions where appetite is reduced.

IMPORTANT SAFETY INFORMATION

ENTYCE® (capromorelin oral solution) is for use in dogs only. Do not use in breeding, pregnant or lactating dogs. Use with caution in dogs with hepatic dysfunction or renal insufficiency.  Adverse reactions in dogs may include diarrhea, vomiting, polydipsia, and hypersalivation. Should not be used in dogs that have a hypersensitivity to capromorelin. Please see the full Prescribing Information for more detail.

  1. Data on file.

Additional resources: